SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers

• Published in: Frontiers in immunology Vol. 13; p. 955800
• Main Authors: Ji, Wenxiang, Niu, Xiaomin, Yu, Yongfeng, Li, Ziming, Gu, LinPing, Lu, Shun
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 03.11.2022
• Subjects: biomarker; immune checkpoint inhibitor; Immunology; pan-cancers; SMO; tumor immune microenvironment (TIME)
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.955800

Background The emergence of immune checkpoint inhibitors (ICIs) is one of the most promising breakthroughs for the treatment of multiple cancer types, but responses vary. Growing evidence points to a link between developmental signaling pathway-related genes and antitumor immunity, but the association between the genomic alterations in these genes and the response to ICIs still needs to be elucidated. Methods Clinical data and sequencing data from published studies and our cohort were collected to analyze the association of the mutation status of SMO with the efficacy of ICI therapy in the non-small cell lung cancer (NSCLC) cohort and the pan-cancer cohort. Furthermore, the correlation between SMO mutation and immunotherapeutic biomarkers such as immune cell infiltration, immune-related genes, and underlying signaling pathways was analyzed. Three SMO mutant plasmids were transfected into cells to explore the SMO mutation status in the context of its expression and cell growth. Result In the NSCLC discovery cohort, the median progression-free survival in the SMO mutant (SMO_MUT) was longer than that in the wild type (SMO_WT) (23.0 vs. 3.8 months, adjusted p  = 0.041). This finding was further confirmed in the NSCLC validation cohort (8.7 vs. 5.1 months, adjusted p  = 0.013). In the pan-cancer cohort ( n  = 1,347), a significant overall survival advantage was observed in patients with SMO mutations [not reached (NR) vs. 18 months, adjusted p  = 0.024]. In the subgroup analysis, the survival advantage of SMO_MUT against SMO_WT was prominent and consistent across genders, ages, treatment types, cancer types, and the tumor mutation burden (TMB) status (all p interaction  > 0.05). In an in vitro experiment, we found that both the mutant and wild-type plasmids can promote the expression of SMO , but the mutant plasmid had lower SMO mRNA and protein levels than the wild type. In CCK-8 experiments, we found that SMO_MUT plasmids can improve the growth of Calu-1 and PC-9 cells, but this capability varied between different mutations and cells. Upon further exploration, the SMO mutation status was found to be related to a higher TMB, more neoantigen load, more DNA damage repair (DDR) mutations, higher microsatellite instability (MSI) score, and higher CD8 + T-cell infiltration. Conclusions The SMO mutation status is an independent prognostic factor that can be used to predict better clinical outcomes of ICI treatment across multiple cancer types.